The company's proprietary Negative EnrichmentTM platform technology is a low-cost and simple sequence-specific enrichment technology that can significantly impact the economics and efficiency of sample preparation, with applications across research, diagnostics, and therapeutics. This unique CRISPR/Cas9 approach can enrich for long DNA fragments out of a complex background and is agnostic to the size of targeted sequence of interest, making it useful for rare event detection as represented in cfDNA (e.g. Liquid Biopsy) and infectious disease diagnostics. Genetics Research's Negative Enrichment™ technology should enable easier detection of tumor-associated mutations in the plasma of cancer patients, resulting in an increase of clinical informativeness in a recurrence population as well as for early detection.